ADVERTISEMENT

Nivolumab immunotherapy not associated with haematological toxicity in cancer patients

Miriam Davis, PhD   |   Clinical Summary   |   10 January 2023
ADVERTISEMENT

Meta-analysis finds lower incidence of haematological toxicity versus similar drugs.

Background

  • The immune checkpoint inhibitor nivolumab is approved in the US and Europe for at least 10 cancer types, including melanoma, non-small cell lung cancer, renal cell carcinoma, and gastric cancer.
  • Nivolumab works by inhibiting the immunosuppressive molecule programmed cell...

          

Topic Challenges

left
right